An interventional study of Training in Menopause, Physical Activity and Prevention, sponsored by University of Poitiers. Completed at 1 site in France. Open to female participants aged 40 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by University of Poitiers · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 368 studies in Motor Activity with a site in France — 77 open to participants now, 89 under way, none of them phase 3. Motor Activity · France.
Among the 368 studies in Motor Activity with a site in France, this one is the 171st largest by enrollment of the 270 interventional ones that give a count, is one of 25 that started in 2022, is one of 255 with no phase, and was the 346th registered.
9,826 studies on the registry are indexed under Motor Activity; 1,911 are open to participants now.
Browse Motor Activity studies →77 of the 368 studies in Motor Activity with a site in France are open now. Recruiting first, the newest first:
Centre Leon Berard · Sites in France
Ages 18+
University Hospital, Grenoble · Sites in France
Ages 18–55 · Healthy volunteers
Groupe Hospitalier du Havre · Sites in France
Ages 18+
University Hospital, Grenoble · Sites in France
Ages 18+
University Hospital, Grenoble · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 1,207 Motor Activity studies recruiting now, 524 (43%) set no upper age limit and 538 (45%) stop at 75 or younger; 180 take children under 18; 420 take healthy volunteers.
This study: 40 Years to 70 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
368 studies; the count open now beside each. This study's row is marked.
First in 1983; this study’s year is marked. 25 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 43 is below the median of 60 across 8,412 interventional studies indexed under Motor Activity.
Median enrollment 62 across the 270 interventional studies, 98 across the 98 observational. Of the 233 that completed or were terminated, 3 (1%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 368 have an industry lead sponsor. The 10 most frequent:
University of Poitiers is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
University of Poitiers has 2 studies filed under Motor Activity — fewer than ten, so there is no comparison to draw.
22 of the studies in Motor Activity with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05641116Centre Hospitalier Universitaire de Saint EtienneEffectiveness of an Intervention Combining Adapted Physical Activity and Therapeutic Education in Patients With Chronic Symptoms Attributed to Lyme Borreliosis. | 2026-12 |
| NCT05770089University Hospital, CaenVideoconferencing Adapted Physical Activity in Anorexia Nervosa: a Pilot Study | 2026-12-01 |
| NCT06061562University Hospital, GrenobleDown Syndrome, Physical Activity and Sleep Apnea | 2026-12-31 |
| NCT05383092University Hospital, ToulouseAdapted Physical Activity for Children Treated With Cancer and Insulin Sensitivity | 2026-12-31 |
| NCT06695780Institut National de Recherche pour l'Agriculture, l'Alimentation et l'EnvironnementFood Typologies and Multidimensional Phenotyping of Elderly in Auvergne-Rhône-Alpes (Part'AGE) | 2027-02 |
Add all 22 to your calendar (.ics) → With an account.
Among the 368 studies in Motor Activity with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide and represent a major public health challenge, with growing evidence highlighting important sex-related differences in their epidemiology, clinical presentation, and pathophysiology. In particular, menopause is associated with an increased cardiovascular risk, likely due to the decline in sex hormones and related changes in cardiac structure and function, vascular properties, and metabolic regulation. Several studies show that physical activity and, more specifically, aerobic training improves exercise tolerance and quality of life in patients. However, no studies have evaluated the effects of hormonal status, despite numerous studies on healthy subjects highlighting the influence of sex hormones on cardiovascular responses to acute and chronic exercise.
Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide and represent a major public health challenge. Importantly, growing evidence highlights significant sex-related differences in the epidemiology, clinical presentation, and pathophysiology of cardiovascular diseases. In particular, postmenopause represents a period of life associated with an increased risk of CVD.
Several physiological mechanisms may underlie these sex-related disparities. Differences in cardiac structure and function, vascular properties, and metabolic regulation contribute to distinct cardiovascular health between men and women. Moreover, the transition to menopause and the associated decline in circulating sex hormones are thought to play a key role in cardiovascular remodeling and functional alterations.
For many years, physical activity has been considered a first-line non-pharmacological strategy in the prevention and treatment of cardiovascular diseases. More specifically, aerobic training has been shown to improves exercise tolerance and quality of life in patients. Indeed, sentinel studies highlight an improvement in aerobic power (VO2 peak) linked to peripheral adaptations (increase in the arteriovenous difference in O2 in the muscles used) and not to central adaptations (no changes in systolic and diastolic functions). However, these studies did not assess the effects of hormonal status , whereas numerous studies on healthy subjects have highlighted the influence of sex hormones on cardiovascular responses to acute and chronic exercise.
The aims of this study:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
24 sessions of adapted physical activity at moderate intensity (aerobic exercise)
Other: Training
Maintaining lifestyle habits
24 sessions of adapted physical activity at moderate intensity (aerobic exercise)
Cardiorespiratory fitness
Maximal cardiopulmonary exercise test (VO2 peak) on a cycloergometer using an incremental protocol, supervised by a cardiologist. The test started at 30 watts, increasing by 15 watts per minute until maximum capacity was reached.
Time frame: At Visit 1 and Visit 3 (30 minutes)
Exercise tolerance
Modified Borg scale during the cardiorespiratory exercise test (scored 0 to 10, higher score indicates lower exercise tolerance).
Time frame: At Visit 1 and Visit 3 (30 minutes)
Muscle oxygenation
Near-infrared spectroscopy is used to measure concentrations of oxygenated and desoxygenated hemoglobin (µmol/L) during the cardiorespiratory exercise test.
Time frame: At Visit 1 and Visit 3 (30 minutes)
Body composition
Percentage of body fat and fat-free mass using the Tanita impedance scale.
Time frame: At Visit 2 and Visit 4 (5 minutes)
Body mass index
Calculated from total body weight and height (kg/m²).
Time frame: At Visit 2 and Visit 4 (5 minutes)
Aortic systolic and diastolic blood pressure
At rest, using the SphygmoCor device, which measures central blood pressure (mmHg).
Time frame: At Visit 2 and Visit 4 (15 minutes)
Arterial stiffness (pulse wave velocity)
At rest, using the SphygmoCor device, which calculates carotid-femoral pulse wave velocity (m/s).
Time frame: At Visit 2 and Visit 4 (15 minutes)
Endothelial function (brachial artery dilation capacity)
At rest, the flow-mediated dilatation technique is used with high-resolution Doppler ultrasound (CX-50 Philipps).
Time frame: At Visit 2 and Visit 4 (30 minutes)
Systolic and diastolic blood pressure (ambulatory blood pressure measurement)
Systolic and diastolic blood pressure profile using the Mobil-O-Graph (mmHg).
Time frame: After Visit 2 and Visit 4 (during 24 hours)
The Menopause-specific Quality of Life Questionnaire (MENQOL)
Composed of 29 items rating the impact of self-reported climateric symptoms in four domains (vasomotor, psychosocial, physical, and sexual).
Time frame: At Visit 2 and Visit 4 (10 minutes)
SF-36 questionnaire
36-item self-report questionnaire measuring health-related quality of life across eight domains (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health)
Time frame: At Visit 2 and Visit 4 (10 minutes)
Age
Age, and menopause age (in years)
Time frame: Baseline
Number of children
Self-reported
Time frame: Baseline
Tobacco use
Current, former, never
Time frame: Baseline
Comorbidities
Time frame: Baseline
Medical treatment
Time frame: Baseline
Physical activity level
Ricci \& Gagnon Questionnaire - Inclusion criteria
Time frame: Baseline (5 minutes)
Blood hormone concentrations
17-beta-estradiol, and follicle-stimulating hormone (ng/L) - Inclusion criteria
Time frame: Baseline
NTproBNP
Biomarker of cardiac insufficiency (pg/mL) - Inclusion criteria
Time frame: Baseline
TSH
Biomarker of uncontrolled thyroid (MUI/L) - Inclusion criteria
Time frame: Baseline
Complete Blood Count
Hemoglobin (g/dL), hematocrit (%) - Inclusion criteria
Time frame: Baseline
Spirometry
FEV₁/FVC ratio - Inclusion criteria
Time frame: At Visit 1 (baseline, 15 minutes)
Stress echocardiography
A progressive incremental exercise test performed on a supine ergometer, combined with echocardiographic measurements taken before, during, and after exercise in order to detect ischemia, contractile abnormalities, valvular dysfunction. - Inclusion criteria
Time frame: At Visit 1 (baseline, 30 minutes)
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Sep 2022 to primary completion in Jun 2025, 33 months.
Of 5,176 non-industry interventional studies with no phase under Motor Activity, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's 33 months is above that.
Counting every sponsor, half of 5,236 studies reached it within 17 months; a quarter within 7 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Poitiers